Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion: PORTAL Study

Sponsors

Lead Sponsor: Samsung Medical Center

Source Samsung Medical Center
Brief Summary

This study is investigator initiated, single-institution, prospective, phase 2 open-label study to determine the efficacy and safety of combination therapy of atezolizumab/bevacizumab and proton beam therapy to portal vein tumor thrombosis with or without main primary tumor in patients with stage 3 or higher hepatocellular carcinoma (HCC) with Vp2-4 portal vein invasion who had not undergone systemic therapy for HCC. The primary endpoint of this study is progression-free survival and secondary endpoints are overall survival (OS), time to progression (TTP), objective response rate, disease control rate (DCR), and time to local disease progression (LTP).

Overall Status Recruiting
Start Date 2022-09-16
Completion Date 2025-12-31
Primary Completion Date 2023-09-30
Phase Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Progression-free survival rate At 9 month
Incidence of adverse event assessed according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0) From date of atezolizumab and bevacizumab initiatton until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months
Secondary Outcome
Measure Time Frame
Overall survival rate At 12 month
Time-to-progression At 9 months
Objective response rate At 3 month
Disease Control rate At 3 month
Local tumor progression rate At 12 month
Enrollment 63
Condition
Intervention

Intervention Type: Radiation

Intervention Name: PBT and atezolizumab/bevacizumab

Description: Atezolizumab 1200 mg and bevacizumab 15 mg/Kg is administered IV infusion every 3 weeks. Proton beam therapy 30 - 50 Gy/5 fractions to portal vein tumor thrombosis with or without main primary tumor after 1 week (+/- 7 days) of 2nd cycle of atezolizumab and bevacizumab The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies.

Arm Group Label: PBT arm

Eligibility

Criteria:

Inclusion Criteria: - Patients with HCC meeting all of following criteria; 1. Histologically or radiologically confirmed hepatocellular carcinoma based on the guidelines of the Korean Liver Cancer Association-National Cancer Center 2022 2. Age >= 20 3. Vp2-4 portal vein tumor thrombosis diagnosed by dynamic enhanced computed tomography (CT) or maganetic resonance images (MRI) with below finding 1) an intraluminal filling defect adjacent to the primary tumor in Vp2-4 portal vein 2) an enhancement of the filling defect on arterial phase and a washout on portal/delayed phases. 4. Signed written informed consent 5. at least one or more measurable intrahepatic viable HCC lesions 6. Child-Pugh class A within 2 weeks from screening for study registration 7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1 within 2 weeks from screening for study registration 8. Life expectancy of at least 16 weeks 9. adequate bone marrow and liver function within 2 weeks from screening for study registration - Hemoglobin ≥ 9.0 g/dL - Absolute neutrophil count (ANC) ≥ 1,000/mm3 - Platelet count ≥ 50,000/μL - Total bilirubin < 2.5 mg/dL - Serum albumin >2.8 g/dL - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × upper limit of normal (ULN) - Prothrombin time in INR ≤ 1.8 × ULN - Serum creatinine ≤ 1.5 mg/dL 10. Women of childbearing potential and men must agree to use highly efficient contraception since signing of the informed consent form until at least 6 months (women) and 7 months (men) after the last study drug administration 11. If other selection conditions are satisfied and the exclusion criteria are not met, registration is possible even in case of N1 or M1. 12. Registration is possible even in the case of hepatic vein tumor infiltration if other selection conditions are satisfied and the exclusion criteria are not met 13. no limitation according to the size and number of tumors in the liver. Exclusion Criteria: Patients with HCC meeting all of following criteria; 1. previous history of systemic treatment for HCC (If systemic treatment for HCC has been performed at least once, it will not be enrolled in this study.) However, registration is permitted if the previous systemic treatment is for adjuvant purposes or treatment for other cancers. Also allowed if previous HCC treatment is local treatment. However, cases with a history of previous upper abdominal radiotherapy (including proton therapy and heavy particle therapy) are excluded. 2. any type of anticancer agent (including investigational) within 2 weeks before enrollment 3. Having active brain metastasis or leptomeningeal metastasis need surgery or steroid therapy 4. Moderate to severe or intractable ascites 5. A history or presence of hepatic encephalopathy 6. Presence of active bacterial infection 7. Untreated active chronic hepatitis B or active hepatitis C 8. History of portal hypertension with bleeding within the past 6 months 9. Prior liver transplant 10. Uncontrolled severe medical comorbidity 11. unhealed wound 12. uncontrolled electrolyte imbalance 13. Non-interruptible therapeutic use of anticoagulants or thrombolytics 14. History of uncontrolled or autoimmune disease, or immunocompromised 15. interstitial lung disease 16. Other malignant disease (a history of treated malignancy -other than HCC- is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding two years) 17. Mentally retarded/medically incapable of consent

Gender:

All

Minimum Age:

20 Years

Maximum Age:

N/A

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Jeong Il Yu, MD, PhD Principal Investigator Samsung Medical Center
Overall Contact

Last Name: Jeong Il Yu, MD, PhD

Phone: 82-2-3410-9598

Email: [email protected]

Location
Facility: Status: Contact: Samsung Medical Center Jeong Il Yu, MD, PhD 82-2-3410-9598 [email protected]
Location Countries

Korea, Republic of

Verification Date

2022-11-01

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Samsung Medical Center

Investigator Full Name: Jeong Il Yu

Investigator Title: Assistant Professor

Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: PBT arm

Type: Experimental

Patient Data Undecided
Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatocellular Carcinoma

Clinical Trials on PBT and atezolizumab/bevacizumab